Related Experiment Video
Updated: Jul 18, 2026

A Novel Surgical Technique As a Foundation for In Vivo Partial Liver Engineering in Rat
Published on: October 6, 2018
Buprenorphine in long-term control of chronic pain in cancer patients
Maria Caterina Pace1, Maria Beatrice Passavanti, Elisa Grella
1Department of Anesthesiology, Surgical and Emergency Sciences, Second University of Naples, Naples, Italy.
Abstract:
The aim of this randomized open-label prospective study was to evaluate the analgesic activity of buprenorphine in a transdermal formulation for cancer chronic pain control versus sustained-release morphine, in all cases combined with oral tramadol. A transdermal system with 35 microg/h buprenorphine was applied to the first group of patients (BT); the second group received 60 mg/day of sustained-release morphine (MT). In both groups oral tramadol was administered to a maximum of 200 mg daily, in case of need. The administration of transdermal buprenorphine versus morphine resulted in significant differences in the physical pain (P = 0.01), mental health (P = 0.03) and vitality (P = 0.001). These data indicated that the BT group showed an improvement of pain and a positive effect on the quality life.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Opioid Analgesics: Morphine and Other Natural Cogeners
Oral Drug Delivery Systems: Continuous-Release Systems
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
